Communiqués Kintor Pharmaceutical Limited OTC Markets

Actions

KNTPF

KYG5273B1077

Recherche biotechnologique et médicale

Marché Fermé - OTC Markets 15:30:02 16/09/2026			Varia. 5j.	Varia. 1 janv.
0,2415 ^USD	+0,62%		-.--%	+11,81%

21/09	Kintor Pharmaceutical Limited annonce la démission de Ming Ming Cheung de ses fonctions de secrétaire général conjoint, avec effet au 21 septembre 2026	CI
07/09	L'action Kintor Pharma progresse : un traitement dermatologique se rapproche de l'homologation après des résultats d'essais	MT

Communiqués

28/10/23	Kintor Pharmaceutical : Pharma Announces Publication of Phase Ib/II Data from GT90001 and Nivolumab Combination Therapy for Advanced HCC in BMC Medicine	PU
11/10/23	Kintor Pharmaceutical : Pharma Announces the Approval of Phase II Clinical Trial of Hedgehog/SMO Inhibitor GT1708F for Treatment of IPF in China	PU
28/08/23	Kintor Pharmaceutical : Pharma Announces 2023 Interim Results and Recent Business Highlights	PU
22/08/23	Kintor Pharmaceutical : Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China	PU
20/07/23	Kintor Pharma Announces Completion of First Patient Enrollment in KX-826 Long-term Safety Phase III Trial for Treatment of AGA	AQ
11/05/23	Kintor Pharmaceutical : Pharma Announces Successful Completion of Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US	PU
08/05/23	Kintor Pharmaceutical : Pharma Announces Successful Completion of Phase I Clinical Trial of GT1708F for Treatment of Hematologic Malignancies in China	PU
18/04/23	Kintor Pharmaceutical : Pharma Announces Completion of Phase I Clinical Trial of GT20029 in the US	PU
14/04/23	Kintor Pharmaceutical : Pharma Announces Completion of First Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China	PU
30/03/23	Kintor Pharma Announces 2022 Annual Results and Recent Business Progress	PR
30/03/23	Kintor Pharmaceutical : Pharma Announces 2022 Annual Results and Recent Business Progress	PU
16/03/23	Kintor Pharmaceutical : Pharma Announces Preclinical Data of GT1708F at AACR 2023	PU
24/11/22	Kintor Pharmaceutical : Pharma Announced Completion of Phase I Trial of the World’s First PROTAC Compound (GT20029) for Topical Use	PU
10/11/22	Kintor Pharmaceutical : Pharma Announces Oral Presentation at ASH 2022 Highlighting the Data from Novel Dual c-Myc/GSPT1 Degrader GT19715	PU
27/10/22	Kintor Pharmaceutical : Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in the US	PU
16/10/22	Kintor Pharmaceutical : Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 for Acne Vulgaris in China	PU
29/09/22	Kintor Pharmaceutical : Phase Ib Data of GT0918 for AR+ mBC Published in EJC	PU
30/08/22	Kintor Pharmaceutical : Pharma Roadshow Presentation	PU
29/08/22	Kintor Pharmaceutical : Pharma Announces 2022 Interim Results and Recent Business Highlights	PU
03/08/22	Kintor Pharmaceutical : Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US	PU
27/06/22	Kintor Pharmaceutical : Pharma Roadshow Presentation	PU
15/05/22	Kintor Pharma Included in MSCI China Index	PR
18/04/22	Kintor Pharmaceutical : Pharma Roadshow Presentation	PU
06/04/22	Kintor Pharmaceutical : Pharma Roadshow Presentation	PU
03/04/22	Kintor Pharmaceutical : Pharma Announces Two Upcoming Poster Presentations at AACR 2022	PU